decline – Talk Bio

Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint

2 months ago talkbio0Tagged Clinical Trials, decline, Effect, Failure (biologic function), Placebos, SPN-820, Supernus Pharmaceuticals, treatment-resistant depression

Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect

Bayer Prepares for Critical Challenges Amid Xarelto Decline

3 months ago talkbio0Tagged Bayer, competition, decline, Drug Industry, earnings, JPM25, Legal patent, strategic plans, Xarelto

Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

3 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients

4 months ago talkbio0Tagged decline, Force, High, Idiopathic Pulmonary Fibrosis, IPF, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology, Vital capacity, Vital capacity test

Deupirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Forced Vital Capacity (FVC), ELEVATE IPF Phase 2b Trial, PureTech Health

Bicycle Therapeutics Faces Stock Decline After Releasing Topline Data and Post-Hoc Analyses

4 months ago talkbio0Tagged Bicycle, cancer trials, decline, EphA2-targeting Bicycle Toxin Conjugate BT5528, metastatic urothelial cancer, Nectin-4 gene, post-hoc analyses, topline, zelenectide pevedotin

Bicycle Therapeutics, stock decline, topline data, post-hoc analyses, cancer trials, zelenectide pevedotin, BT5528, metastatic urothelial cancer, Nectin-4 gene amplification.

PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial

4 months ago talkbio0Tagged decline, Fibrosis, High, Idiopathic Pulmonary Fibrosis, Lung, LYT 100, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology

PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment